Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

As previously presented, gedatolisib + palbociclib + fulvestrant ('gedatolisib triplet”) and gedatolisib + fulvestrant ('gedatolisib doublet”) reduced the risk of disease progression or death versus ...

When Jon and Dayla Culp received the news that their six-year-old Labrador retriever, Clarice, had a malignant tumor near her left wrist, the couple was devastated. Dayla had lost her sister, Darcy ...

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

Editor’s note: This round‑up is based on press releases, peer‑reviewed publications, and company communications received in January and February 2026. All results are preliminary unless stated, and ...

Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper deal and raising £8.5 million.

Awareness Month, which raises awareness, action, and amplifies the voices of individuals impacted by MM, a blood cancer in which abnormal plasma cells build up in the bone marrow, producing large ...

Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained ...

BrYet US, Inc. (“BrYet”) — a biotechnology innovator focused on developing curative therapies for advanced cancers — ...

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies ...

Neoadjuvant pembrolizumab (3 doses) in stage I–III disease yielded a 71% pCR rate and only one melanoma-specific survival event at 3 years post-resection. Experts discuss the SWOG S1512 trial of ...

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that ...